He Lian, Lu Anjing, Qin Lin, Zhang Qianru, Ling Hua, Tan Daopeng, He Yuqi
The Key Laboratory of Basic Pharmacology of Minstry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, School of Pharmacy, Zunyi Medical University, Zunyi, China.
Shanghai Nature-Standard Technology Service Co., Ltd., Shanghai, China.
Ann Transl Med. 2021 Oct;9(20):1598. doi: 10.21037/atm-21-4824.
OBJECTIVE: This review aimed to summarize the application of single-cell transcriptome sequencing technology in liver diseases. BACKGROUND: The increasing application of single-cell ribonucleic acid (RNA) sequencing (scRNA-seq) in life science and biomedical research has greatly improved our understanding of cellular heterogeneity in immunology, oncology, and developmental biology. scRNA-seq has proven to be a powerful tool for identifying and classifying cell subsets, characterizing rare or small cell subsets and tracking cell differentiation along the dynamic cell stages. Globally, liver disease has high rates of morbidity and mortality, and its exact pathological mechanism remains unclear, current treatment options are limited to clearance of the underlying cause or liver transplantation, which cannot overwhelm and cure liver diseases. scRNA-seq provides many novel insights for healthy and diseased livers. METHODS: In this review, we searched for related articles in the PubMed database and summarized the advances of scRNA-seq in revealing the molecular mechanisms of liver development, regeneration, and disease. We also discussed the challenges and future application potential of scRNA-seq, which is expected to enhance the ability to explore the field of liver research and accelerate the clinical application of liver precision medicine. CONCLUSIONS: With the continuous improvement of scRNA-seq technology, scRNA-seq is expected to unlock new avenues for liver biology exploration, liver disease diagnosis, and personalized treatment, which will pave the way for breakthrough innovation in personalized medicine.
目的:本综述旨在总结单细胞转录组测序技术在肝脏疾病中的应用。 背景:单细胞核糖核酸(RNA)测序(scRNA-seq)在生命科学和生物医学研究中的应用日益增加,极大地提高了我们对免疫学、肿瘤学和发育生物学中细胞异质性的理解。scRNA-seq已被证明是一种强大的工具,可用于识别和分类细胞亚群、表征罕见或小细胞亚群以及追踪细胞在动态细胞阶段的分化。在全球范围内,肝脏疾病的发病率和死亡率都很高,其确切的病理机制仍不清楚,目前的治疗选择仅限于消除潜在病因或进行肝移植,这些方法无法彻底战胜和治愈肝脏疾病。scRNA-seq为健康和患病肝脏提供了许多新的见解。 方法:在本综述中,我们在PubMed数据库中搜索了相关文章,并总结了scRNA-seq在揭示肝脏发育、再生和疾病分子机制方面的进展。我们还讨论了scRNA-seq面临的挑战和未来的应用潜力,预计这将增强探索肝脏研究领域的能力,并加速肝脏精准医学的临床应用。 结论:随着scRNA-seq技术的不断改进,scRNA-seq有望为肝脏生物学探索、肝脏疾病诊断和个性化治疗开辟新途径,这将为个性化医学的突破性创新铺平道路。
Ann Transl Med. 2021-10
Cell Regen. 2023-2-3
Comput Struct Biotechnol J. 2020
Stem Cells. 2024-1-13
Biology (Basel). 2024-6-19
FEBS Open Bio. 2025-9
Diab Vasc Dis Res. 2025
Medicine (Baltimore). 2024-2-23
Cell Mol Gastroenterol Hepatol. 2021
Nat Protoc. 2020-6-19
Nat Biotechnol. 2020-4-6
Immunology. 2020-4-15
Hepatology. 2020-4
Infect Genet Evol. 2020-6